India-based CRO enters US market to support global research

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/dk_photos)
(Image: Getty/dk_photos)

Related tags: CRO, Clinical trials, Lambda Therapeutic Research, Novum Pharmaceutical Research Services

Lambda Therapeutic Research is extending its global footprint to the US with the acquisition of Novum Pharmaceutical Research Services, a CRO based in Pittsburgh, PA.

While Lambda’s first US-based facility, Novum will be the company’s second in North America following its 2010 acquisition of Biovail’s R&D facilities in Canada. The India-headquartered contract research organization (CRO) also has offices in Poland and the UK.

Following the transaction, Novum will retain its identity and operate as a division of Lambda led by CEO Christopher Chamberlain, who will manage US operations.

The deal – which Chamberlain called “a powerful strategic move between two like-minded CROs with many years of experience” – ​also marks Lambda’s entrance into the US market

“There will also be a wide array of high-quality services under one umbrella that will greatly benefit customers. Both companies have extensive experience with early and late phase research, but specialize in somewhat complementary niches,”​ he told us.

“The combined company will allow clients to conduct many types of late phase research on a global scale, pursue large molecule and highly complex trials, including 505(b)(2) programs, patient studies, and topical and transdermals,”​ added Chamberlain.

Clients also will have access to bioanalytical capabilities, pharmacovigilance, and imaging services.

As per integration, Chamberlain said all plans are in active development as the companies close the transaction, financial terms of which have not been disclosed.

Related news

Show more

Related products

show more

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 15-Aug-2022 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Standardizing data with NCI controlled terminology

Standardizing data with NCI controlled terminology

Formedix | 18-Jul-2022 | Technical / White Paper

The use of consistent terminology within and between studies is critical to enabling an efficient trial process. CDISC standards such as CDASH, SDTM, SEND...

Related suppliers

Follow us


View more